Hybio Pharmaceutical (300199) — Working Capital to Net Assets Ratio
Hybio Pharmaceutical (300199) has a Working Capital to Net Assets ratio of -142.9% as of September 2025. Working capital of CN¥-951.59 Million (current assets of CN¥565.09 Million minus current liabilities of CN¥1.52 Billion) is measured against net assets of CN¥666.08 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See 300199 equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hybio Pharmaceutical Working Capital to Net Assets (2007–2024)
This chart shows how Hybio Pharmaceutical's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at -142.9%, reflecting working capital of CN¥-951.59 Million against net assets of CN¥666.08 Million CNY. Check tangible net worth ratio of Hybio Pharmaceutical to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Hybio Pharmaceutical (2007–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hybio Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300199 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -161.0% | CN¥-961.51 Million | CN¥597.05 Million | CN¥463.05 Million | CN¥1.42 Billion | ▼ -66.6 pp |
| 2023 | -94.5% | CN¥-739.80 Million | CN¥783.21 Million | CN¥683.64 Million | CN¥1.42 Billion | ▼ -68.6 pp |
| 2022 | -25.9% | CN¥-335.63 Million | CN¥1.30 Billion | CN¥812.32 Million | CN¥1.15 Billion | ▼ -50.8 pp |
| 2021 | 25.0% | CN¥411.26 Million | CN¥1.65 Billion | CN¥1.16 Billion | CN¥743.82 Million | ▲ +27.9 pp |
| 2020 | -3.0% | CN¥-49.98 Million | CN¥1.68 Billion | CN¥1.05 Billion | CN¥1.10 Billion | ▼ -36.9 pp |
| 2019 | 33.9% | CN¥757.06 Million | CN¥2.23 Billion | CN¥1.89 Billion | CN¥1.14 Billion | ▼ -30.7 pp |
| 2018 | 64.6% | CN¥2.19 Billion | CN¥3.39 Billion | CN¥3.02 Billion | CN¥831.93 Million | ▲ +19.9 pp |
| 2017 | 44.6% | CN¥1.73 Billion | CN¥3.88 Billion | CN¥2.60 Billion | CN¥865.01 Million | ▲ +2.7 pp |
| 2016 | 41.9% | CN¥1.51 Billion | CN¥3.60 Billion | CN¥1.84 Billion | CN¥330.92 Million | ▲ +20.7 pp |
| 2015 | 21.2% | CN¥560.29 Million | CN¥2.64 Billion | CN¥979.38 Million | CN¥419.09 Million | ▼ -46.1 pp |
| 2014 | 67.3% | CN¥872.52 Million | CN¥1.30 Billion | CN¥990.66 Million | CN¥118.14 Million | ▲ +14.8 pp |
| 2013 | 52.6% | CN¥590.81 Million | CN¥1.12 Billion | CN¥667.20 Million | CN¥76.39 Million | ▼ -20.3 pp |
| 2012 | 72.9% | CN¥740.44 Million | CN¥1.02 Billion | CN¥789.94 Million | CN¥49.50 Million | ▼ -19.1 pp |
| 2011 | 92.0% | CN¥898.16 Million | CN¥976.09 Million | CN¥927.75 Million | CN¥29.59 Million | ▲ +27.0 pp |
| 2010 | 65.0% | CN¥117.40 Million | CN¥180.59 Million | CN¥133.10 Million | CN¥15.71 Million | ▲ +19.4 pp |
| 2009 | 45.6% | CN¥58.31 Million | CN¥127.74 Million | CN¥112.62 Million | CN¥54.31 Million | ▲ +13.1 pp |
| 2008 | 32.5% | CN¥32.30 Million | CN¥99.23 Million | CN¥69.41 Million | CN¥37.11 Million | ▼ -24.5 pp |
| 2007 | 57.1% | CN¥27.79 Million | CN¥48.70 Million | CN¥37.34 Million | CN¥9.54 Million | — |